Literature DB >> 26970483

Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT).

Zheng Cai1, Zhiqiang Zhu2, Mark I Greene2, Douglas B Cines2.   

Abstract

Autoantigen development is poorly understood at the atomic level. Heparin-induced thrombocytopenia (HIT) is an autoimmune thrombotic disorder caused by antibodies to an antigen composed of platelet factor 4 (PF4) and heparin or cellular glycosaminoglycans (GAGs). In solution, PF4 exists as an equilibrium among monomers, dimers and tetramers. Structural studies of these interacting components helped delineate a multi-step process involved in the pathogenesis of HIT. First, heparin binds to the 'closed' end of the PF4 tetramer and stabilizes its conformation; exposing the 'open' end. Second, PF4 arrays along heparin/GAG chains, which approximate tetramers, form large antigenic complexes that enhance antibody avidity. Third, pathogenic HIT antibodies bind to the 'open' end of stabilized PF4 tetramers to form an IgG/PF4/heparin ternary immune complex and also to propagate the formation of 'ultralarge immune complexes' (ULCs) that contain multiple IgG antibodies. Fourth, ULCs signal through FcγRIIA receptors, activating platelets and monocytes directly and generating thrombin, which transactivates hematopoietic and endothelial cells. A non-pathogenic anti-PF4 antibody prevents tetramer formation, binding of pathogenic antibody, platelet activation and thrombosis, providing a new approach to manage HIT. An improved understanding of the pathogenesis of HIT may lead to novel diagnostics and therapeutics for this autoimmune disease.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmunity; FcγRIIA; Heparin-induced thrombocytopenia; Immune complex structure; Pathogenesis

Mesh:

Substances:

Year:  2016        PMID: 26970483      PMCID: PMC4875785          DOI: 10.1016/j.autrev.2016.03.011

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  42 in total

Review 1.  Clinical practice. Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  N Engl J Med       Date:  2006-08-24       Impact factor: 91.245

Review 2.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Heparin-induced thrombocytopenia associated with fondaparinux.

Authors:  Theodore E Warkentin; Brian T Maurer; Richard H Aster
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

4.  Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies.

Authors:  G M Arepally; S Kamei; K S Park; K Kamei; Z Q Li; W Liu; D L Siegel; W Kisiel; D B Cines; M Poncz
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

5.  Crystal structure of recombinant human platelet factor 4.

Authors:  X Zhang; L Chen; D P Bancroft; C K Lai; T E Maione
Journal:  Biochemistry       Date:  1994-07-12       Impact factor: 3.162

6.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.

Authors:  K A Bauer; B I Eriksson; M R Lassen; A G Turpie
Journal:  N Engl J Med       Date:  2001-11-01       Impact factor: 91.245

7.  NMR solution structure of the 32-kDa platelet factor 4 ELR-motif N-terminal chimera: a symmetric tetramer.

Authors:  K H Mayo; V Roongta; E Ilyina; R Milius; S Barker; C Quinlan; G La Rosa; T J Daly
Journal:  Biochemistry       Date:  1995-09-12       Impact factor: 3.162

8.  Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.

Authors:  T E Warkentin; C P Hayward; L K Boshkov; A V Santos; J A Sheppard; A P Bode; J G Kelton
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

9.  Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Mortimer Poncz; Steven E McKenzie; Michael P Reilly; Gowthami Arepally; John W Weisel; Chandrasekaran Nagaswami; Douglas B Cines; Bruce S Sachais
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

10.  Atomic description of the immune complex involved in heparin-induced thrombocytopenia.

Authors:  Zheng Cai; Serge V Yarovoi; Zhiqiang Zhu; Lubica Rauova; Vincent Hayes; Tatiana Lebedeva; Qun Liu; Mortimer Poncz; Gowthami Arepally; Douglas B Cines; Mark I Greene
Journal:  Nat Commun       Date:  2015-09-22       Impact factor: 14.919

View more
  5 in total

Review 1.  Molecular and cellular pathogenesis of heparin-induced thrombocytopenia (HIT).

Authors:  Lubica Rauova; Gowthami Arepally; Mortimer Poncz; Douglas B Cines
Journal:  Autoimmun Rev       Date:  2018-08-10       Impact factor: 9.754

2.  Dimeric FcγR ectodomains detect pathogenic anti-platelet factor 4-heparin antibodies in heparin-induced thromobocytopenia.

Authors:  B D Wines; C W Tan; E Duncan; S McRae; R I Baker; R K Andrews; S Esparon; E E Gardiner; P M Hogarth
Journal:  J Thromb Haemost       Date:  2018-11-20       Impact factor: 5.824

Review 3.  Elucidation of Cellular Contributions to Heparin-Induced Thrombocytopenia Using Omic Approaches.

Authors:  Jason B Giles; Elise C Miller; Heidi E Steiner; Jason H Karnes
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

4.  Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia.

Authors:  Christine S M Lee; Maria V Selvadurai; Leonardo Pasalic; James Yeung; Maria Konda; Geoffrey W Kershaw; Emmanuel J Favaloro; Vivien M Chen
Journal:  J Thromb Haemost       Date:  2022-02-07       Impact factor: 16.036

5.  Anti-neutrophil cytoplasmic antibody-associated vasculitis accompanied by type II heparin-induced thrombocytopenia resulting in asymptomatic cerebral infarction: a case report.

Authors:  Yoshitaka Furuto; Mariko Kawamura; Jumpei Yamashita; Takahiro Yoshikawa; Akio Namikawa; Rei Isshiki; Hiroko Takahashi; Yuko Shibuya
Journal:  BMC Nephrol       Date:  2021-06-14       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.